A5003405177- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Breast Implant and Reconstruction
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Caveolin-1 and cellular processes
- Radiopharmaceutical Chemistry and Applications
- Cancer Diagnosis and Treatment
- Cancer Risks and Factors
- Colorectal Cancer Treatments and Studies
- Biosimilars and Bioanalytical Methods
- Cancer, Lipids, and Metabolism
Helios Hospital Berlin-Buch
2016-2025
Helios Kliniken
2014-2025
Universidad Europea de Madrid
2024
Klinik für Frauenheilkunde
2005-2023
Ludwig-Maximilians-Universität München
2004-2023
Medizinische Hochschule Hannover
2018-2023
University Medical Center Hamburg-Eppendorf
2009-2023
Universität Hamburg
2009-2023
University Hospital Schleswig-Holstein
2011-2022
University of Lübeck
2011-2022
Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage completion chemotherapy.
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Purpose The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor at surgery association with long-term outcome 6,377 patients primary receiving neoadjuvant anthracycline-taxane–based chemotherapy seven randomized trials were analyzed. Results Disease-free (DFS) was significantly superior no invasive situ residuals or nodes (n = 955) compared residual ductal carcinoma only 309), but...
Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients early triple-negative breast cancer. Whether the addition of to neoadjuvant chemotherapy would significantly increase percentage cancer who have a pathological complete response (defined as no invasive negative nodes) at definitive surgery is unclear.
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy a worse prognosis than those no cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent (DM1), maytansine derivative microtubule inhibitor, provides benefit in patients with metastatic that was previously treated HER2-targeted therapy.
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) immunologically relevant genes neoadjuvant GeparSixto trial. Patients Methods investigated effect adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response...
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here, we explore the therapeutic potential lapatinib by testing its effect on tumor cell in panel 31 characterized human breast cancer lines, including trastuzumab-conditioned HER-2-positive lines. We further characterize activity combination with trastuzumab analyze whether EGFR expression or changes induced activation EGFR, HER-2, Raf, AKT, extracellular...
Neoadjuvant (primary systemic) treatment is the standard for locally advanced breast cancer and a option primary operable disease. Because of new treatments understandings cancer, however, recommendations published in 2003 regarding neoadjuvant disease required updating. Therefore, second international panel representatives number clinical research groups was convened September 2004 to update these recommendations. As part this effort, data date were reviewed critically indications newly defined.
Background: HER-2/neu, which encodes a receptor tyrosine kinase, is amplified and overexpressed in 20%–25% of human breast cancers. Such tumors are often resistant to hormone therapy. Despite general inverse association between HER-2/neu amplification/overexpression estrogen (ER) and/or progesterone (PR) expression, fraction patients both HER-2/neu- (HR)-positive. The efficacy therapy this group currently matter debate. To better understand the relationship positivity HR we analyzed ER, PR...
PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively investigated its given simultaneously with anthracycline-taxane-based neoadjuvant chemotherapy. PATIENTS AND METHODS Patients operable or locally advanced, HER2-positive tumors were treated preoperatively four cycles of epirubicin/cyclophosphamide followed by docetaxel without capecitabine (EC-T[X]) and trastuzumab 6 mg/kg...
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal receptor 2 (HER2)–negative metastatic breast cancer. We evaluated the efficacy, measured according to rate of pathological complete response (absence invasive and intraductal disease axillary lymph nodes), safety adding bevacizumab neoadjuvant chemotherapy early-stage
Purpose To evaluate efficacy and safety of epirubicin cyclophosphamide followed by paclitaxel trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer. Patients Methods centrally confirmed HER2-overexpressing cancer (≥ cm or inflammatory) received four 3-week cycles (90/600 mg/m ) (175 (6 mg/kg) before surgery. Trastuzumab was continued after surgery to complete 1 year treatment. Primary end point pathologic response...
This study was aimed at detecting and characterizing circulating tumor cells (CTC) before after neoadjuvant therapy (NT) in the peripheral blood of patients with breast cancer.The clinical trial GeparQuattro incorporated NT approaches (epirubicin/cyclophosphamide prior to randomization docetaxel alone, combination capecitabine, or followed by capecitabine) additional trastuzumab treatment for HER2-positive tumors. We used Food Drug Administration-approved CellSearch system CTC detection...